Get the Stockscreener App
0.34
4.25%
-0.0151
After Hours:
.34
Passage Bio Inc stock is traded at $0.34, with a volume of 386.02K.
It is down -4.25% in the last 24 hours and down -20.08% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$0.3551
Open:
$0.36
24h Volume:
386.02K
Relative Volume:
1.23
Market Cap:
$21.13M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.2906
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
-10.76%
1M Performance:
-20.08%
6M Performance:
-47.61%
1Y Performance:
-74.91%
1-Day Range:
$0.3307
$0.40
1-Week Range:
$0.3247
$0.42
52-Week Range:
$0.3247
$1.64
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.34 | 21.13M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Fierce Biotech Layoff Tracker 2025: Sail cuts staff; Carisma and Inspirna shutter - Fierce Biotech
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq
Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Passage BIO, Inc. SEC 10-K Report - TradingView
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:07 am EST - Marketscreener.com
Passage Bio Reports Promising Interim Data for PBFT02 in FTD-GRN Patients and Provides Business Updates - Nasdaq
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent - The Bakersfield Californian
Can Passage Bio's FTD-GRN Treatment Breakthrough Translate to Market Success? - StockTitan
Passage Bio to Present at Two Major Investor Conferences - MSN
Passage Bio (PASG) to Release Quarterly Earnings on Monday - Defense World
Passage Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 10 '25 |
Sale |
0.66 |
126,209 |
83,298 |
7,131,636 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 14 '25 |
Sale |
0.60 |
79,024 |
47,414 |
7,034,626 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 13 '25 |
Sale |
0.64 |
17,986 |
11,511 |
7,113,650 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 08 '25 |
Sale |
0.68 |
75,007 |
51,005 |
7,257,845 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 07 '25 |
Sale |
0.71 |
52,536 |
37,301 |
7,332,852 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 06 '25 |
Sale |
0.77 |
19,481 |
15,000 |
7,385,388 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):